培美曲塞联合顺铂或卡铂治疗复发或转移性非小细胞肺癌63例疗效分析

背景与目的对初治后复发或转移性非小细胞肺癌(non-smallcelllung cancer,NSCLC)患者的治疗,需引入新的二线药物及治疗方法。培美曲塞为多靶点抗叶酸化疗药物,近来多用于NSCLC的治疗。本研究旨在探讨培美曲塞联合顺铂或卡铂方案治疗复发或转移性NSCLC的疗效以及不良反应。方法经病理学或细胞学确诊的复发或转移性晚期NSCLC患者63例,其中男性40例,女性23例,中位年龄62岁。培美曲塞500mg/m2第1天+顺铂30mg/m2第1、2、3天或卡铂300mg/m2第1天静脉滴注,每3周重复。评价疗效及不良反应。结果 63例中完全缓解1例,部分缓解5例,稳定36例,进展21例,疾病控制率为66.7%(42/63),中位生存期为9.0个月。中位无疾病进展时间为5.0个月,其中鳞癌为3.0个月,腺癌为5.5个月,非鳞癌优于鳞癌,差异有统计学意义(P=0.017)。主要不良反应为粒细胞下降、贫血和胃肠道反应。结论培美曲塞联合顺铂或卡铂方案治疗复发或转移性NSCLC疗效确切,对非鳞癌更具有治疗优势。不良反应发生率低,耐受性较好。

Pemetrexed Combined with Cisplatin or Carboplatin Regimen in the Treatment of Advanced Recurrent or Metastasis Non-small Cell Lung Cancer:Analysis of 63 Cases

Background and objective Since the poor outcome for advanced lung cancer with first-line chemotherapy,more efforts should be paid for treatment of advanced recurrent or metastasis non-small cell lung cancer(NSCLC) patients.Pemetrexed,as a multi-target antifolate chemotherapeutic drug,was approved for the second-line treatment of advanced NSCLC.The aim of this study is to evaluate the efficacy and side effects of pemetrexed combined with cisplatin/carboplatin in the treatment of advanced recurrent or metasta...